ANG Lifesciences appoints Preeti Sarin as Additional Independent Director for five-year term
BSE India
ANG Lifesciences board approves the appointment of Mrs. Preeti Sarin as an Additional Independent Director for a five-year term effective November 14, 2026. The board also takes note of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The appointment follows the recommendation of the Nomination & Remuneration Committee and remains subject to shareholder approval.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 20.10 15.30 26.05 31.39% -22.85%
EBITDA -0.15 -1.85 0.20 91.62% -176.38%
Op. profit margin(%) -1.31 -12.77 0.31 89.73% -527.63%
Net Profit -2.09 -4.24 -2.95 50.79% 29.14%
EPS -1.59 -3.24 -2.24 50.93% 29.02%
* Consolidated data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 19.01 26.67 5.15 -28.72% 268.75%
EBITDA 0.42 0.60 0.11 -29.27% 284.42%
Op. profit margin(%) 1.83 1.08 0.10 68.90% 1646.11%
Net Profit 0.18 0.39 0.06 -54.22% 223.20%
EPS 0.01 0.01 0.03 0.00% -66.67%
* Consolidated data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 7.75 7.20 3.86 7.59% 100.69%
EBITDA 4.55 5.33 -3.49 -14.64% 230.34%
Op. profit margin(%) 50.65 53.06 -117.83 -4.55% 142.98%
Net Profit 3.69 3.72 -4.52 -0.76% 181.73%
EPS 0.87 1.01 -3.61 -13.86% 124.10%
* Consolidated data
6.28
-1.72%
Easy Trip Planners reports Q2FY27 results and CMO Manmeet Ahluwalia tenders resignation
BSE India
Easy Trip Planners board approves unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The announcement also confirms the resignation of CMO Manmeet Ahluwalia, effective November 30, 2026. The filing includes the independent auditor's review report on the consolidated quarterly and year-to-date results.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 157.99 134.71 118.34 17.29% 33.51%
EBITDA 8.93 -6.31 -38.88 241.58% 122.97%
Op. profit margin(%) -0.70 -9.56 3.35 92.72% -120.81%
Net Profit 0.10 -11.41 -32.70 100.89% 100.31%
EPS 0.01 -0.03 -0.09 122.00% 107.33%
* Consolidated data
24.51
4.92%
Glaam Up Jwel board approves unaudited standalone financial results for H1FY27
BSE India
Glaam Up Jwel board of directors approves the standalone unaudited financial results for the half year ended September 30, 2026. The announcement includes the accompanying Auditor's Review Report as required under SEBI Listing Obligations and Disclosure Requirements. The filing serves as a formal regulatory disclosure of the company's mid-year financial standing.
38.51
-2.51%
FlyHi Maritime Travels board approves unaudited standalone financial results for H1FY27
BSE India
FlyHi Maritime Travels board approves the unaudited standalone financial results for the half year ended September 30, 2026. The announcement includes the statement of assets and liabilities along with the statement of cash flow. The statutory auditors also issued a limited review report on these standalone financial results. The filing serves as a formal disclosure of the company's performance for the first half of the fiscal year.
ANG Lifesciences approves Q2FY27 unaudited financial results and appoints Mrs. Preeti Sarin as Additional Independent Director
BSE India
ANG Lifesciences board approves the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026. The company also takes note of the appointment of Mrs. Preeti Sarin as an Additional Independent Director for a five-year term starting November 14, 2026. The board also receives the limited review report from M/s Khurana Sharma & Co regarding these financial results. This announcement includes the requisite disclosures as per SEBI Listing Regulations.
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 20.10 15.30 26.05 31.39% -22.85%
EBITDA -0.15 -1.85 0.20 91.62% -176.38%
Op. profit margin(%) -1.31 -12.77 0.31 89.73% -527.63%
Net Profit -2.09 -4.24 -2.95 50.79% 29.14%
EPS -1.59 -3.24 -2.24 50.93% 29.02%
* Consolidated data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 34.01 24.98 26.94 36.15% 26.23%
EBITDA -0.25 -0.27 6.25 8.31% -104.03%
Op. profit margin(%) -0.83 -1.51 5.20 44.75% -116.00%
Net Profit -2.81 -2.65 3.85 -5.74% -172.79%
EPS -6.81 -9.67 14.04 29.58% -148.50%
* Standalone data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 7.75 7.20 3.86 7.59% 100.69%
EBITDA 4.55 5.33 -3.49 -14.64% 230.34%
Op. profit margin(%) 50.65 53.06 -117.83 -4.55% 142.98%
Net Profit 3.69 3.72 -4.52 -0.76% 181.73%
EPS 0.87 1.01 -3.61 -13.86% 124.10%
* Consolidated data